 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- |||| 611 / 3SBio
New P1/2 trial: Evaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - Mar 22, 2024
P1/2, N=104, Not yet recruiting, Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- || 611 / 3SBio
New P1/2 trial: Evaluation of 611 in Chinese Adult Patients With Moderate-to-Severe Atopic Dermatitis (clinicaltrials.gov) - Dec 7, 2022
P1/2, N=24, Completed, Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- || 611 / 3SBio
Trial completion: Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers (clinicaltrials.gov) - Nov 10, 2022
P1, N=40, Completed, Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Not yet recruiting --> Completed
- ||| 611 / 3SBio
Enrollment open: SSGJ-611-AD-II-01: Evaluation of 611 in Chinese Adults With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - Nov 3, 2022
P2, N=90, Recruiting, Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Not yet recruiting --> Completed Not yet recruiting --> Recruiting
- |||| 611 / 3SBio
New P2 trial: SSGJ-611-AD-II-01: Evaluation of 611 in Chinese Adults With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - Sep 16, 2022
P2, N=90, Not yet recruiting, Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- || 611 / 3SBio
New P1 trial: Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers (clinicaltrials.gov) - Aug 25, 2020
P1, N=40, Not yet recruiting, Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.